Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
KesimptaⓇ - CD20 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03650114 ALITHIOS (COMB157G2399)
Multiple Sclerosis
Phase 3
2010
Evaluate the long-term safety and tolerability of ofatumumab 20 mg subcutaneous
(sc) once every 4 (94) weeks in subjects with RMS from the first dose of
ofatumumab
Ofatumumab 20 mg every 4 weeks
Patients with relapsing MS
Target Patients
Read-out Milestone(s)
2028
Publication
TBD
98 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation